Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Jorge E. Cortes, Dong-Wook Kim, Franck E Nicolini, Tapan Saikia, Aude Charbonnier, Jane F. Apperley, Krishna Rathnam, Michael W. Deininger, Hugues De Lavallade, Navin Khattry, Andrew Whiteley, Michael J. Mauro, Gregor Verhoef, Carlo Gambacorti-Passerini, Alessandro Lucchesi, Shashikant Apte, Granacher Nikki, Siu-Long Yao, Mudgal Kothekar, Jayasree Sreenivasan, Bimba HV, Geetanjali Chimote
Institutions: The University of Texas MD Anderson Cancer Center, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Centre Léon Bérard, Prince Aly Khan Hospital, Institut Paoli-Calmettes, Imperial College London, Meenakshi Mission Hospital and Research Centre, University of Utah, Huntsman Cancer Institute, King's College London, King's College Hospital NHS Foundation Trust, King's College Hospital, Tata Memorial Hospital, Advanced Centre for Treatment, Research and Education in Cancer, Baylor University Medical Center, Memorial Sloan Kettering Cancer Center, Universitair Ziekenhuis Leuven, University of Milano-Bicocca, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Sahyadri Hospital, Ziekenhuisnetwerk Antwerpen Stuivenberg, Sun Pharma (India), Sun Pharma Advanced Research (India)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2989040643